Navigation Links
Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
Date:1/31/2013

SANDY, Utah, Jan. 31, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol "RAFA" announced that it has been named one of the four national strategic Pharmaceutical Suppliers to the Russian Federation.  This important step for the company means it will receive guaranteed government contracts helping load the manufacturing facility to 100% capacity.

The Russian pharmaceutical industry supplies both the national health care system and hospital sector with 70% of medicines in physical volume. The Russian pharmaceutical market is considered to be one of the most dynamic and growing in the world. It continues to grow an average 10-12% per year since 2003 (Source: The Strategy of Development of the Pharmaceutical Industry of the Russian Federation, http://www.osec.ch/de/filefield-private/files/25703/field_blog_public_files/5244).

CEO David Anderson stated, "This is a very exciting time for the Company and we are extremely happy with the ability to be one of the four national strategic Pharmaceutical Suppliers to the Russian Federation."

As previously announced the Company will facilitate investor awareness using social media.  Follow Rafarma Pharmaceuticals on Facebook at www.facebook.com/rafarmainfo or Twitter at www.twitter.com/rafarmainfo. You can also text "RAFA" to 74499 to receive updates via text message.

Safe Harbor Statement 

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate,"  "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.


'/>"/>
SOURCE Rafarma Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Issuance of $350.0 Million of 1.50% Convertible Senior Notes Due 2018
2. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
3. Ryan & Maniskas, LLP Announces Investigation of MAP Pharmaceuticals, Inc.
4. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
5. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
6. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
8. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
9. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
10. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
(Date:12/2/2016)...  Today, Simpson Healthcare Executives, a global leader in ... as winners of multiple awards at the 2016 MarCom ... PLATINUM level, Blue Zones Menu at the GOLD Level, ... and our proprietary 3ConneX Platform at the HONORABLE MENTION ... are excited to showcase our new Platinum and Gold ...
(Date:12/2/2016)... 2016 The iShares Nasdaq Biotechnology Exchange-Traded ... Trump,s victory early in November. Less political risk has ... now predicting an uptick in M&A activities. Today, Stock-Callers.com ... how they have fared at the last close: Celldex ... Inc. (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering local frontline ... field of pain management. , The demand for supplemental training related to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in ... fits into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started ... how the details line up exactly with Bible Prophecy – a protected way for ...
Breaking Medicine News(10 mins):